Canadian Cancer Trials Group Bulletins

General


Recent Publication

A recent publication reports the results of a pooled analysis of Canadian Cancer Trials Group BR.10 (A Phase III Prospective Randomized Study of Adjuvant Chemotherapy with Vinorelbine and Cisplatin in Completely Resected Non-Small Cell Lung Cancer with Companion Tumour Marker Evaluation) and CALGB B-9633 (Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer) which explored the prognostic and predictive effects of the new T-size descriptors and KRAS mutation status in patients with node-negative NSCLC.

Cuffe S, Bourredjem A, Graziano S, Pignon JP, Domerg C, Ezzalfani M, Seymour L, Strevel E, Burkes R, Capelletti M, Jšnne PA, Tsao MS, Shepherd FA. A Pooled Exploratory Analysis of the Effect of Tumor Size and KRAS Mutations on Survival Benefit From Adjuvant Platinum-Based Chemotherapy in Node-Negative Non-Small Cell Lung Cancer. J Thoracic Oncol 7: 963-72, 2012.

http://journals.lww.com/jto/Fulltext/2012/06000/A_Pooled_Exploratory_Analysis_of_the_Effect_of.3.aspx